Development and Evaluation of Novel Encapsulated Isoeugenol-Liposomal Gel Carrier System for Methicillin-Resistant...

Area of Science:

• Pharmacology
• Nanotechnology
• Microbiology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat.
• Development of novel, plant-derived therapies is crucial for combating MRSA.
• Molecular docking identified isoeugenol as a potential anti-MRSA agent targeting penicillin-binding protein 2a.

Purpose of the Study:

• To develop and characterize a liposomal gel formulation of isoeugenol for potential MRSA treatment.
• To evaluate the physical properties, safety, and in vitro efficacy of the isoeugenol-liposomal gel.

Main Methods:

• Isoeugenol was encapsulated into a liposomal carrier system.
• Liposomal formulation characterized for encapsulation efficiency, particle size, zeta potential, and morphology.
• Formulation incorporated into a Carbopol gel and evaluated for physical properties (pH, viscosity, spreadability).
• In vitro safety (cell viability) and drug release studies were conducted.
• Minimum Inhibitory Concentration (MIC) was determined.

Main Results:

• Liposomal encapsulation achieved 57.8% entrapment efficiency, with particle size of 143.31 nm and a zeta potential of -25 mV.
• The isoeugenol-liposomal gel exhibited suitable physical properties (pH 6.4, good viscosity, spreadability) and was safe for human use (>80% cell viability).
• In vitro studies showed 75.95% drug release after 24 hours and an MIC of 8.236 µg/mL.

Conclusions:

• Liposomal encapsulation of isoeugenol provides a stable and effective delivery system.
• The developed isoeugenol-liposomal gel demonstrates significant potential as a topical therapeutic agent for MRSA infections.
• Further investigation into this novel formulation is warranted for clinical application.